TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Ovid Therapeutics
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Ovid Therapeutics announced a CEO succession plan with Meg Alexander becoming CEO on January 1, 2026, and Dr. Jeremy M. Levin transitioning to Executive Chair. The company reported positive Phase 1 results for OV329, a next-generation GABA-AT inhibitor, and continues advancing its KCC2 direct activator portfolio.

Insights
AMZN   positive

Extended post-earnings surge, climbing 4.7% after Friday's 9.6% rally


OVID   positive

Demonstrated strong clinical trial results for OV329, completed a significant private placement raising $175 million, progressing multiple drug development programs, and executing a strategic leadership transition